← Leaderboards
Alexandra L Howell
White River Junction Va Medical Center
$0
Attributed
$0
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2009–24$1$1$1$0$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
VA$0 · 3
By mechanism
I01$0 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Immune System”
- Lawrence Corey · Fred Hutchinson Cancer Center$527,549,553
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$327,516,759
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$314,842,858
- Barton F Haynes · Duke University$254,474,833
- Judith S. Currier · University Of California Los Angeles$247,114,730
- Peter B. Gilbert · Fred Hutchinson Cancer Center$210,957,667
Research focus
Immune SystemInfectionMediatingPharmaceutical PreparationsCcr5 GeneCellsHiv-1In VivoReceptorImmuneCd4 Positive T LymphocytesAnti-Retroviral AgentsInterruptionHiv ResistanceHuman DiseaseHiv InfectionsInnovationIn VitroGuide RnaFlow CytometryGenesBaseBindingHematopoietic Stem Cells
Grant awards (12)
Developing novel CRISPR/CasX editors to generate a CCR5/null immune system$0
I01 · FY2024 · VA · contact PI
Developing novel CRISPR/CasX editors to generate a CCR5/null immune system$0
I01 · FY2023 · VA · contact PI
Developing novel CRISPR/CasX editors to generate a CCR5/null immune system$0
I01 · FY2022 · VA · contact PI
Developing novel CRISPR/CasX editors to generate a CCR5/null immune system$0
I01 · FY2021 · VA · contact PI
Combination Therapy Using CRISPR/Cas Gene Editing Plus Human Monoclonal Antibodies for a Functional HIV Cure$0
I01 · FY2019 · VA · contact PI
Combination Therapy Using CRISPR/Cas Gene Editing Plus Human Monoclonal Antibodies for a Functional HIV Cure$0
I01 · FY2018 · VA · contact PI
Combination Therapy Using CRISPR/Cas Gene Editing Plus Human Monoclonal Antibodies for a Functional HIV Cure$0
I01 · FY2017 · VA · contact PI
Combination Therapy Using CRISPR/Cas Gene Editing Plus Human Monoclonal Antibodies for a Functional HIV Cure$0
I01 · FY2016 · VA · contact PI
Inhibiting Mucosal HIV-1 Transmission by Host Cell RNA Interference$0
I01 · FY2013 · VA · contact PI
Inhibiting Mucosal HIV-1 Transmission by Host Cell RNA Interference$0
I01 · FY2012 · VA · contact PI
Inhibiting Mucosal HIV-1 Transmission by Host Cell RNA Interference$0
I01 · FY2011 · VA · contact PI
Inhibiting Mucosal HIV-1 Transmission by Host Cell RNA Interference$0
I01 · FY2009 · VA · contact PI